Sihuan Pharm announced that its non-wholly-owned subsidiary, Huisheng Pharm, has completed a RMB 500 million Series A financing. This round was invested by China Life Chengda (Shanghai) Health Industry Equity Investment Centre (L.P.), GF Investment, GF Investment Ji Mao, and GINKGO Capital.

CEC Capital acted as the exclusive financial advisor for Huisheng Pharm in this transaction.

Expanding its presence in the multi-billion-dollar diabetes market, Sihuan Pharm established Huisheng Pharm in 2014, to focus on diabetes and its complications. After seven years of development and an investment exceeding RMB 1.5 billion, Huisheng Pharm now has a team of over 200 professionals. The company has successfully developed a comprehensive product pipeline, with nearly 40 different stages of diabetes products, covering a wide range of targets. The product line includes second, third, and fourth-generation insulin and analogs (covering basal, premix, and rapid-acting products), as well as the latest innovative drugs such as SGLT-2, GLP-1, DPP-4, and other mechanisms for glucose-lowering and complications treatment.